Myriad Genetics Inc. (MYGN) was a big mover last session, as the company saw its shares rise by over 15% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up roughly 49% in the past one-month time frame.
This healthcare company has seen three estimate revisions in the past 30 days and its Zacks Consensus Estimate moved lower over the time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.
Myriad Genetics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Some better-ranked stocks in the same industry include Affymetrix Inc. (AFFX), Actelion Ltd. (ALIOF) and Alexion Pharmaceuticals, Inc. (ALXN). All these stocks hold a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
MYRIAD GENETICS INC (MYGN): Free Stock Analysis Report
AFFYMETRIX INC (AFFX): Free Stock Analysis Report
ACTELION LTD (ALIOF): Free Stock Analysis Report
ALEXION PHARMACEUTICALS INC (ALXN): Free Stock Analysis Report
Zacks Investment Research